drugset / Trial / NCT05970822

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

NCT05970822

Phase 1 Unknown 32 enrolled Biocity Biopharmaceutics Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of BC3402 in combination with azacitidine (AZA) in subjects with Myelodysplastic Syndrome (MDS) and Chronic myelomonocytic leukemia (CMML)

Timeline

Start
2023-06-18
Primary completion
2025-03
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BC3402 Monoclonal antibody Intravenous
Background Azacitidine Other / unclassified